Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.73 |
| ▸ | CES1 | P23141 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.72 |
| ▸ | CA2 | P00918 | 2/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430882 | 0.87 | CES2 (0.67) | CES2CES1CA1CA2BCHE | |
| SCHEMBL223704 | 0.85 | CES1 (1.00) | CES2CES1CA1CA2BCHE | |
| SCHEMBL6259754 | 0.84 | CA1 (0.94) | CES2CES1CA1CA2BCHE | |
| Paraoxon SCHEMBL26405 | 0.84 | CA1 (1.00) | CES2CES1CA1CA2BCHE | |
| Paraoxon SCHEMBL21114409 | 0.84 | CA1 (1.00) | CES2CES1CA1CA2BCHE | |
| SCHEMBL11588711 | 0.83 | CES1 (0.96) | CES2CES1CA1CA2BCHE | |
| SCHEMBL11588705 | 0.83 | CES1 (0.96) | CES2CES1CA1CA2BCHE | |
| Bromide SCHEMBL11420868 | 0.83 | CES1 (0.96) | CES2CES1CA1CA2BCHE | |
| Water SCHEMBL9045475 | 0.83 | CES1 (0.96) | CES2CES1CA1CA2BCHE | |
| SCHEMBL3860441 | 0.83 | ALDH1A1 (0.73) | CES2CES1CA1CA2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20210107942-A1 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS INC (US) | 2021-04-15 | — | — | US | disclosed |
| WO-2021024141-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | LI XIAOXIANG (CN) | 2021-02-11 | — | — | WO | disclosed |
| US-10864253-B2 | Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage | ARAIM PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200360476-A1 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20190134156-A1 | TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2017189988-A1 | TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170232066-A1 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-9580465-B2 | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | ARAIM PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160168199-A1 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-8853358-B2 | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | ARAIM PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110263504-A1 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| CN-102066413-A | Tissue protective peptides and peptide analogs for the prevention and treatment of diseases and disorders associated with tissue damage | ARAIM PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | disclosed |
| EP-2245056-A2 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Araim Pharmaceuticals, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009094172-A2 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-6765104-B1 | Transition metal complexes of n, n',n″trialkyl-cis-1,3,5-triaminocyclohexane and related compositions and methods of synthesis and use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-07-20 | — | — | US | disclosed |
| WO-2001010870-A1 | TRANSITION METAL COMPLEXES OF N,N',N'-TRIALKYL- CIS,CIS-1,3,5-TRIAMINOCYCLOHEXANE AND RELATED COMPOSITIONS AND METHODS OF SYNTHESIS AND USE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-0777485-A4 | 2',5' PHOSPHOROTHIOATE/PHOSPHODIESTER OLIGOADENYLATES AND ANTIVIRAL USES THEREOF | UNIV TEMPLE (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0777485-A1 | 2',5' PHOSPHOROTHIOATE/PHOSPHODIESTER OLIGOADENYLATES AND ANTIVIRAL USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996008256-A1 | 2',5' PHOSPHOROTHIOATE/PHOSPHODIESTER OLIGOADENYLATES AND ANTIVIRAL USES THEREOF | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | CES2 3550/4885CES1 1220/4885CA1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.